Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models.

@article{Li2015DoxorubicinloadedPN,
  title={Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models.},
  author={Mingqiang Li and Zhaohui Tang and Dawei Zhang and Hai Sun and Huaiyu Liu and Ying Zhang and Yuanyuan Zhang and Xuesi Chen},
  journal={Biomaterials},
  year={2015},
  volume={51},
  pages={
          161-172
        }
}
As a synergistic drug combination, doxorubicin-loaded cisplatin crosslinked polysaccharide-based nanoparticles (Dex-SA-DOX-CDDP) have demonstrated enhanced antitumor efficacy and reduced systemic toxicity via optimized biodistribution, controlled drug release, prolonged blood circulation, and improved tolerability, compared to the non-crosslinked nanoparticles or free doxorubicin. Herein, we apply the Dex-SA-DOX-CDDP nanoparticles as an efficient antitumor agent to treat colorectal and breast… Expand
Redox‐responsive microbeads containing thiolated pectin‐doxorubicin conjugate inhibit tumor growth and metastasis: An in vitro and in vivo study
TLDR
These novel coated microbeads containing thiolated pectin–DOX conjugate may be a promising vehicle for targeted clinical delivery of DOX to the colorectal cancer site by oral administration. Expand
Targeted hydroxyethyl starch prodrug for inhibiting the growth and metastasis of prostate cancer.
TLDR
Targeted HES-DOX/LHRH possesses great potential application in clinical chemotherapy of metastatic prostate cancer, and exhibited higher levels of anti-tumor and anti-metastasis activities against an RM-1-xenografted mouse model. Expand
Tumor microenvironment-responsive hyaluronate-calcium carbonate hybrid nanoparticle enables effective chemotherapy for primary and advanced osteosarcomas
Osteosarcoma is the most common malignancy in the bone. Current chemotherapy offers limited efficacy with significant side effects, especially for advanced and relapsed osteosarcomas.Expand
Neutralizing tumor-promoting inflammation with polypeptide-dexamethasone conjugate for microenvironment modulation and colorectal cancer therapy.
TLDR
The results suggest that anti-inflammatory drugs hold great potential in modulating the tumor microenvironment when delivered properly, and can also result in significant tumor inhibition effects. Expand
Targeted delivery of doxorubicin and vincristine to lymph cancer: evaluation of novel nanostructured lipid carriers in vitro and in vivo
TLDR
DOX/VCR NLCs were proved to be more efficacious than the equivalent dose of free DOX and single drug (DOX or VCR) formulation in vitro and in vivo, and significantly reduced the drug-associated systemic toxicity. Expand
Self-targeting visualizable hyaluronate nanogel for synchronized intracellular release of doxorubicin and cisplatin in combating multidrug-resistant breast cancer
TLDR
A type of self-targeting hyaluronate (HA) nanogels to reverse drug resistance through the synchronized pharmacokinetics, intratumoral distribution, and intracellular release of topoisomerase II inhibitor doxorubicin (DOX) and DNA-crosslinking agent cisplatin (CDDP) is developed. Expand
CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
TLDR
The multifunctional DOX-AMD-DNG can effectively target the tumor site and dually impede cancer progression and metastasis and displayed superior anticancer activity and antimetastatic effects in orthotopic breast cancer-bearing Balb/C mice. Expand
Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
TLDR
By responding to the acidic pHs of tumor microenvironment and intracellular organelles, this multifunctional nanoparticle system could release R848 extracellularly and deliver DOX targetedly to breast cancer cells, thus achieving synergistic effects of immunotherapy and chemotherapy against breast cancer. Expand
Construction and application of a liver cancer-targeting drug delivery system based on core–shell gold nanocages
TLDR
The in vitro and in vivo results confirmed that the tumor-targeting and controlled-release drug system DOX/AuNCs-PM-HA with the combination of chemotherapy and photothermal therapy showed strong anti-tumor effect and would have great potential for future cancer therapy. Expand
Self‐Stabilized Hyaluronate Nanogel for Intracellular Codelivery of Doxorubicin and Cisplatin to Osteosarcoma
TLDR
CDDP‐crosslinked DOX‐loaded nanomedicine (CDDPHANG/DOX) reveals an evidently enhanced antitumor efficacy compared to free drugs and their combination, indicating its great prospects for the chemotherapy of osteosarcoma. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds.
TLDR
It is demonstrated that doxorubicin-tethered gold nanoparticles via a poly(ethylene glycol) spacer and an acid-labile hydrazone bond mediate potent doxorbicin delivery to breast CSCs, which reduces their mammosphere formation capacity and their cancer initiation activity, eliciting marked enhancement in tumor growth inhibition in murine models. Expand
Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy.
TLDR
The in vivo toxicity evaluation demonstrates that nanoparticle substantially avoids DOX-related toxicities and presents good biosafety without obvious side effects to normal organs of both tumor-bearing and healthy mice. Expand
Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.
TLDR
In vitro cytotoxicity assays against A549 human lung adenocarcinoma cell line demonstrated that the DOX + PTX co-delivered nanoparticles (Co-NPs) exhibited synergistic effect in inducing cancer cell apoptosis, indicating this co- delivery system with different functional antitumor drugs provides the clinical potential in cancer therapy. Expand
Reversibly stabilized multifunctional dextran nanoparticles efficiently deliver doxorubicin into the nuclei of cancer cells.
TLDR
These nanoparticles were prepared from dextran-lipoic acid derivatives and were readily cross-linked using a catalytic amount of dithiothreitol (DTT) and showed a similar drug efficacy as the non-cross-linked counterparts. Expand
Doxorubicin-loaded boron-rich polymer nanoparticles for orthotopically implanted liver tumor treatment
The in vivo behaviors of doxorubicin (DOX)-loaded dextran-poly(3-acrylamidophenylboronic acid) (Dextran-PAPBA) nanoparticles (NPs) were studied. The DOX-loaded NPs had a narrowly distributed diameterExpand
Doxorubicin-loaded silk films: drug-silk interactions and in vivo performance in human orthotopic breast cancer.
TLDR
Results suggest that the future use of this approach for localised chemotherapy is promising, and stabilised silk films loaded with doxorubicin also reduced metastatic spread and autopsy indicated that these films were not associated with any local or systemic toxicities. Expand
Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles.
TLDR
In vivo antitumor efficacy showed that PTPNs could not only inhibit the in situ tumor growth effectively, but also completely restrict the pulmonary metastasis in 4T1 pulmonary metastatic mice model, indicating synergistic effect for the effective therapy of metastatic breast cancer. Expand
Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer.
TLDR
It is suggested that P-HA-NPs can be used as a versatile theranostic system for the early detection, targeted therapy, and therapeutic monitoring of colon cancer. Expand
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
TLDR
Mouse tumor models show that coinjection of the iRGD peptide increases the tumor penetration and antitumor activity of several cancer drugs, including the cytotoxic agent doxorubicin and the therapeutic antibody trastuzumab (Herceptin), without increasing their harmful effects on healthy tissue. Expand
Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells.
In this study, thioridazine (THZ), which was reported to kill cancer stem cells, was used in a combination therapy with doxorubicin (DOX) to eradicate both cancer cells and DOX-resistant cancer stemExpand
...
1
2
3
4
5
...